TESARO Announces Submission of Rolapitant New Drug

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
TESARO Announces Submission of Rolapitant New Drug Application (NDA) to U.S. Food and Drug Administration

WALTHAM, Mass., Sept. 8, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq: TSRO ), an oncology-focused biopharmaceutical company, today announced that it has submitted the New Drug Application (NDA) for oral rolapitant to the U.S. Food and Drug Administration (FDA). Rolapitant is an investigational neurokinin-1 (NK-1) receptor antagonist developed for the prevention of chemotherapy-induced nausea and vomiting (CINV).

"TESARO is committed to advancing new therapeutic options for patients with cancer, and the oral rolapitant NDA submission represents a significant milestone for the Company," said Mary Lynne Hedley, Ph.D., President and COO of TESARO. "We believe rolapitant could become an important new treatment for the prevention of nausea and vomiting for patients undergoing emetogenic chemotherapy."

The oral rolapitant NDA is supported by data from four controlled studies covering a spectrum of patients receiving emetogenic chemotherapy. One study enrolled patients receiving Moderately Emetogenic Chemotherapy (MEC), and three studies enrolled patients receiving cisplatin-based Highly Emetogenic Chemotherapy (HEC). The top-line results of each of the three Phase 3 studies of rolapitant were previously announced by TESARO and were presented in detail at the American Society for Clinical Oncology (ASCO) annual meeting in June 2014.

About Rolapitant

Rolapitant is a potent and selective NK-1 receptor antagonist with an extended plasma half-life that is being developed for the prevention of CINV. NK-1 receptors are highly concentrated in the brain and bind the neurokinin substance P. Activation of NK-1 receptors plays a central role in nausea and vomiting induced by emetogenic stimuli, including certain cancer chemotherapies. NK-1 receptor antagonists have been demonstrated to improve the management of nausea and vomiting experienced by cancer patients undergoing emetogenic chemotherapy. The safety and tolerability of single and repeat doses of rolapitant have been assessed in more than 2,500 healthy volunteers and patients. Rolapitant is being developed both in oral and intravenous formulations. TESARO licensed exclusive rights for the development, manufacture, commercialization and distribution of rolapitant from OPKO Health, Inc.

About Chemotherapy-Induced Nausea and Vomiting (CINV)

CINV is estimated to afflict over 70% of cancer patients undergoing emetogenic chemotherapy and, if not prevented, may possibly result in a delay or even discontinuation of chemotherapy treatment. Prolonged nausea and vomiting may result in unwanted weight loss, dehydration and malnutrition, as well as hospitalization. 

About TESARO

TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapeutics. For more information, visit www.tesarobio.com .

To the extent that statements contained in this press release are not descriptions of historical facts regarding TESARO, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the initiation and conduct of clinical trials, expectations with respect to regulatory submissions and approvals, challenges associated with expanding operations to include commercial activities, and other matters that could affect the availability or commercial potential of our drug candidates. TESARO undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see TESARO's Annual Report on Form 10-K for the year ended December 31, 2013 and other filings TESARO makes with the Securities and Exchange Commission.

Investor/Media Contact: Jennifer Davis Sr. Director, Corporate Development & Investor Relations +1.781.325.1116 or

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ave7® Pioneers AI-Driven Marketplace Evolution

Updated Category News Views 15

AI Reshapes the Agency Paradigm Nobody saw this coming a decade ago, but here we are—AI's taking the wheel, but with humans still riding shotgun. The agency world, particularly the one dealing with e-commerce giants like Amazon, Walmart, and Target, has flipped on its head. Ave7® steps up as the frontrunner, adapting faster than a broker's reflex after a market bell....

Continue Reading
Flexible Packaging Market to Hit $384.32B by 2031

Updated Category News Views 45

Packaging's Flexible Future Alright, here's the skinny: you might want to adjust those portfolios if you're watching the materials sector, because the flexible packaging market ain't just loosening up—it's stretching out like never before. By 2031, we're talking about it raking in a solid $384.32 billion, climbing from $313.25 billion in 2026. That's a not-so-shabby...

Continue Reading
Exploring Creation: A Fresh Look at Genesis

Updated Category News Views 67

Opening Up Genesis in a New Light Hey, if you’re like most folks, you’ve probably heard Genesis framed as the battleground for science versus religion debates, right? Enter into this mix a fresh take with Robert E. Franzen’s new book, The Narration of Creation. This book asks you to overlook those grand philosophical fights and instead focus on the narrative itself....

Continue Reading
Giovanni Recalde Sues County After False Report

Updated Category News Views 43

Justice and Reputation: A Mix-Up Costs Big When the cops screw up, sometimes they really take the cake. That's what Giovanni Recalde learned, the hard way, when his name got tangled in a mess related to a gambling operation he wasn't even a part of. Prince William County police pasted his name into their daily incident report last year like it was no big deal. But it...

Continue Reading
Gwen Stefani Kicks Off OCVIBE's New Concert Hall

Updated Category News Views 132

A Homecoming Steeped in Nostalgia Orange County’s about to do a serious throwback, folks! Gwen Stefani is set to headline the opening concert at OCVIBE's spanking new concert hall in Anaheim on March 17, 2027. Curious choice for their opener? Hardly. This gal's practically woven into the county’s tapestry—her roots run deep here, enough to make even the casual music...

Continue Reading
Mall of America Strives for World Record This Black Friday

Updated Category News Views 228

History in the Making at Mall of America Yeah, it seems these folks are not just about shopping anymore. The Mall of America is aiming to set the bar high this Black Friday, eyeing a GUINNESS WORLD RECORDS title for the most people holding up the same shopping bag all at once. Imagine a thousand people, synchronized like a flash mob—only with shopping bags instead of...

Continue Reading
IQSTEL's Nine-Month Revenue Hits $313M, Growth Impresses

Updated Category News Views 69

Pushing Through With Persistence Well, well, well, here we are, talking about IQSTEL Inc. (NASDAQ: IQST) slinging some serious numbers—not the kind you can ignore at your breakfast table. The company pulled in a whopping $313 million in revenue over the first nine months of 2026. That’s a bump up by 34.5% from last year’s $232.7 million. What’s behind the magic...

Continue Reading
Tenax Therapeutics Facing Class Action: DEC 28 Deadline

Updated Category News Views 70

Legal Storm Over Tenax Therapeutics Just what the doctor didn't order—legal headaches for Tenax Therapeutics, Inc. (NASDAQ:TENX). Yup, folks, buckle up because we're diving into another class action mudslinging match that’s setting the markets wagging. Berger Montague's law trebuchet is aimed squarely at Tenax and every investor should know the target’s outline....

Continue Reading
Dawson Struggles With Q3 Losses Despite Growth Prospects

Updated Category News Views 74

Profit and loss dance around like a jittery stock, and Dawson Geophysical is feeling the heat this third quarter. Numbers are in, and we’re seeing a net loss of $5.2 million, translating to $0.17 per share—ouch. Not to mention a negative Adjusted EBITDA of $2 million. Compared to last year's hopes, that's a serious belly flop. Revenue Down, Hopes Up In a fetching...

Continue Reading
Disney+ Teams Up with Tiff's: Blue Cookie Debut

Updated Category News Views 34

A Sweet Collaboration on the Horizon If somebody had told me that cookies could conjure up excitement equivalent to a TV show's new season, I'd have laughed. But here we are—Disney+ and Tiff's Treats are cooking up a storm with blue chocolate chip cookies to celebrate 'Percy Jackson and the Olympians' Season 3 premiere. The Cookie That Packs a Punch Forget ordinary...

Continue Reading

Top 5 Most Recently Viewed Articles

US Agriculture Partners with CeresAI for Enhanced Farming Insights

Updated Category News Views 168

US Agriculture and CeresAI: A Groundbreaking Collaboration In an innovative move, US Agriculture, LLC has teamed up with CeresAI to transform farmland monitoring through advanced technology. This partnership aims to leverage artificial intelligence for improved performance in agricultural investments by optimizing farmland management and reducing costs associated with...

Continue Reading
Infosys Launches New Zurich Office to Drive AI Innovations

Updated Category News Views 175

Infosys Expands Its Zurich Office for Enhanced Client Collaboration Infosys, a global trailblazer in digital services and consulting, has inaugurated its new office in Zurich, Switzerland, marking a pivotal moment in its 25-year journey within the Swiss market. With this move, Infosys not only relocates its Swiss headquarters to The Circle at Zurich Airport but also...

Continue Reading
SierraConstellation Partners Celebrates Significant Award Wins

Updated Category News Views 117

A Major Milestone for SierraConstellation Partners SierraConstellation Partners (“SCP”), a foremost interim management and advisory firm, has received several prestigious awards for its outstanding work in business restructuring. The Global M&A Network has recognized SCP's exemplary handling of both the sale of Vyera Pharmaceuticals' assets and the reorganization of...

Continue Reading
Kaltura's AI Innovations Recognized in Market Guide

Updated Category News Views 179

Kaltura's Recognition in the Industry Kaltura, a leader in AI Video Experience Cloud technology, has recently been acknowledged as a Representative Vendor in the Gartner Market Guide for Video Platform Services. This recognition is a testament to Kaltura's forward-thinking approach and its commitment to enhancing enterprise video solutions. The Importance of Video...

Continue Reading
Liberty Gold’s Annual Meeting Outcomes: New Leadership and Directions

Updated Category News Views 288

Liberty Gold Announces Annual General Meeting Results Vancouver, British Columbia – Liberty Gold Corp. (TSX: LGD; OTCQX: LGDTF) has shared the outcomes of its recent Annual General Meeting (AGM) where shareholders participated in crucial decisions shaping the future leadership of the company. The AGM marked a significant moment for Liberty Gold as it transitions into a...

Continue Reading